中华皮肤科杂志 ›› 2013, Vol. 46 ›› Issue (8): 588-590.

• 研究报道 • 上一篇    下一篇

白芍总苷联合依巴斯汀治疗慢性特发性荨麻疹疗效观察

梁云生1,张桂英1,文海泉2   

  1. 1. 中南大学湘雅二医院
    2. 长沙中南大学湘雅二医院皮肤科
  • 收稿日期:2012-12-17 修回日期:2013-05-08 出版日期:2013-08-15 发布日期:2013-08-01
  • 通讯作者: 梁云生 E-mail:yunshengliang@yahoo.com.cn

Clinical observations on the efficacy of total glucosides of paeony combined with ebastine in the treatment of chronic idiopathic urticaria

yunsheng LIANG 2   

  • Received:2012-12-17 Revised:2013-05-08 Online:2013-08-15 Published:2013-08-01
  • Contact: yunsheng LIANG E-mail:yunshengliang@yahoo.com.cn

PDF

4

赞

摘要： 【摘要】 目的 观察白芍总苷联合依巴斯汀治疗慢性特发性荨麻疹的临床疗效和安全性。方法 采用随机、开放、阳性药物、平行对照研究方法，按随机数字表将60例慢性特发性荨麻疹患者随机分为2组，联合治疗组30例，口服白芍总苷600 mg每日3次，依巴斯汀10 mg/d；对照组口服依巴斯汀10 mg/d。疗程12周，停药后观察4周，以7 d荨麻疹活动评分（UAS7）评价疗效，记录不良反应。结果 治疗第8周、第12周、停药第4周（第16周），联合治疗组UAS7（分别为9.28 ± 4.59、5.83 ± 4.44、7.52 ± 5.57）明显低于对照组（分别为13.29 ± 4.72、9.86 ± 5.46、16.21 ± 5.34），两组差异均有统计学意义。在治疗第12周时，联合治疗组有效率（75.9%）明显高于对照组（42.9%），差异有统计学意义（χ2 = 4.56，P ＜ 0.05）。停药后第4周，联合治疗组复发率（13.6%）明显低于对照组（50.0%），差异有统计学意义（χ2 =3.90，P ＜ 0.05）。两组未见明显不良反应。结论 白芍总苷能够明显提高依巴斯汀治疗慢性特发性荨麻疹的疗效，并降低复发率。

关键词: 荨麻疹, 白芍总苷, 依巴斯汀

Abstract: LIANG Yun-sheng, ZHANG Gui-ying, WEN Hai-quan. Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha 410011, China 【Abstract】 Objective To evaluate the efficacy and safety of total glucosides of paeony combined with ebastine for the treatment of chronic idiopathic urticaria. Methods A randomized, open-labeled, positive drug-controlled, parallel-group study was carried out. Sixty patients with chronic idiopathic urticaria were randomly divided into two groups using a random digit table: combined group treated with total glucosides of paeony 600 mg thrice daily combined with ebastine 10 mg per day, control group treated with ebastine 10 mg per day only. The treatment lasted 12 weeks followed by a four-week follow-up． Adverse reactions were recorded and treatment efficacy was evaluated by using urticaria activity score over seven days （UAS7）. Results The UAS7 was 9.28 ± 4.59, 5.83 ± 4.44 and 7.52 ± 5.57 in the combined group on week 8, 12 after the initiation of treatment and week 4 after the withdrawal of treatment, respectively, significantly lower than that in the control group at the three time points （13.29 ± 4.72, P < 0.05; 9.86 ± 5.46, P < 0.01; 16.21 ± 5.34, P < 0.01）. Significant differences were observed in the response rate between the combined group and control group at the end of the 12-week treatment （75.9% vs. 42.9%, χ2 = 4.56, P < 0.05）. There was a decreased recurrence rate in the combined group combined with the control group at the end of the follow-up （13.6% vs. 50.0%, χ2 = 3.90, P < 0.05）. No obvious adverse reactions were noted in either of the two groups. Conclusion Total glucosides of paeony could markedly enhance the efficacy of ebastine for the treatment of chronic idiopathic urticaria with a reduction in recurrence rate.

Key words: ebastine